Ciklodekstrini –primjena u različitim načinima isporuke lijekova by SHYAM SHIMPI et al.
INTRODUCTION
Cyclodextrins (CDs), cyclic oligosaccharides, were discovered approximately 100
years ago. CDs have been used as solubilizers, stabilizers for biological active substan-
ces, enzyme models, as separating agents in chromatography or batch processes, cata-
lysts and additives (as detergents, viscosity modifiers, etc.) (1).
CDs can be used to reduce or prevent gastrointestinal (GI) or ocular irritation, re-
duce or eliminate unpleasant smell or taste, prevent drug-drug or drug-additive interac-
tions, or even to convert oils and liquid drugs into microcrystalline or amorphous pow-
der. CDs can be also used as processing aid to isolate a specific compound from natural
sources and to remove an unwanted compound such as cholesterol from food products.
Marketed CDs are well accepted because of their low oral and local toxicity, low eye
and mucous irritability, easy availability, etc. Some points must be considered while pre-
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paring the CD derivatives, such as that they must be produced by a simple reaction,
must be non-toxic, must have an acceptable price, must retain the complex forming ca-
pacity and must possess advantageous properties for some specific application.
CHEMISTRY AND PROPERTIES OF CDs
More than 1500 different CD derivatives have been described in the literature. Gen-
erally, CDs can be divided into naturally occurring and chemically modified CDs (2).
Another classification is based on their water solubility (Table 1), so one can distinguish
hydrophilic, lipophilic and ionizable derivatives. Pitha (3) classified the two ways of de-
rivatization, vertical (axial) and horizontal cavity modifications. Horizontal modificati-
on is done by enzymes cyclodextrin glucanotransferase yielding natural -, -, - and
larger CDs. -CD, -CD and -CD differ from each other depending on the presence of
glucose residue (Fig. 1). Vertical cavity modification is done by chemical substitution,
which elongates the CD torus in an axial direction by introducing larger substituents.
Some water soluble CD derivatives that are available and expected to have commercial
pharmaceutical applications are methylated derivatives of -CD, 2-hydroxypropylated
- and -CDs, sulfobutylated--CD, branched CDs (glucosyl- and maltosyl--CD), acety-
lated - and -CD and sulfated CDs (4). When CDs are modified, the solubility can in-
crease or decrease. Modification of the 2- or 3- hydroxyl group results in disruption of
the hydrogen bonding occurring around the ring of the CD molecule. The disruption al-
lows more interactions of these hydroxyl groups with water molecules, resulting in al-
tered solubility, e.g. methylated -CD shows an aqueous solubility up to 50 fold higher
than that of unsubstituted -CD (5, 6).
Complexation of molecules to CDs occurs through a non-covalent interaction be-
tween the molecule and the CD cavity. This is a dynamic process whereby the guest mo-
lecule continuously associates and dissociates from the host CD. CDs are insoluble in
most organic solvents; they are soluble in some polar, aprotic solvents. Although the so-
lubility of CDs is higher in some organic solvents than in water, complexation may not
occur readily in non-aqueous solvents because of the increased affinity of the guest for
the solvent compared to its affinity for water. Also CDs form complexes with lipophilic
solvents, even with ethanol and methanol, and these complexes become contaminants in
the final product. CDs glass transition occurs at about 225 to 250 °C. The glass transition
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Table I. Molecular properties of CDs
Parameter
-CD -CD -CD
Glucose residue 6 7 8
Molecular mass 973 1135 1297
Cavity diameter (nm) 0.47–0.53 0.6–0.66 0.75–0.83
Cavity height (nm) 0.79 0.79 0.79
Cavity volume (mL mol–1) 174 262 472
Solubility (mg mL–1 at 25 °C) 130 18.5 300
temperature varies with the degree of substitution. Thermal decomposition occurs at
308 °C. Strong acids such as hydrochloric acid and sulfuric acid hydrolyze CDs. The rate
of hydrolysis is dependent upon temperature and concentration of the acid. CDs are sta-
ble against bases. HP--CD can be hydrolyzed by some amylases at a very slow rate
compared to the corresponding unsubstituted CD. The greater the degree of substitu-
tion, the less hydrolysis occurs. Substitution provides hindrance to the binding of CD to
the active site of the enzyme; as a result, the extent of hydrolysis is reduced (7).
COMPLEXATION AND THE MECHANISM OF DRUG RELEASE FROM CD COMPLEXES
The internal cavity, hydrophobic in nature, is a key feature of the CDs providing the
ability to form complexes, which include a variety of guest molecules. CD inclusion is a
stoichiometric molecular phenomenon in which usually only one molecule interacts with
the cavity of the CD molecule to become entrapped. A variety of non-covalent forces,
such as van der Waals forces, hydrophobic interactions and other forces are responsible
for the formation of the stable complex. Inclusion complex formation can be regarded as
’encapsulation’ of the drug molecule, or at least the labile part of the molecule. The en-
capsulation protects the drug molecule against attack by various reactive molecules and
in this way reduces the rate of hydrolysis, oxidation, stearic rearrangement, racemiza-
tion and even enzymatic decomposition (8). In addition, CDs can decrease the photo
degradation of various light sensitive drugs (9, 10).
Many techniques are used to form CD complexes, like co-precipitation, slurry com-
plexation, paste complexation, damp mixing, heating method, extrusion and dry mix-
ing. The name itself describes the process of complex formation.
141





































Fig. 1. Structure of -CD.
Co-precipitation. – CD is dissolved in water and the guest is added while stirring the
CD solution. By heating, more CD can be dissolved (20%) if the guest can tolerate the
higher temperature. The CD and guest solution must be cooled under stirring before a
precipitate is formed. The precipitate can be collected by decanting, centrifugation or fil-
tration and washed. The main disadvantage of this method lies in the scale-up.
Slurry complexation. – CD can be added to water, as much as 50–60% solids, and stirred.
The aqueous phase will be saturated with CD in solution. Guest molecule will complex
with the CD in solution and, as the CD complex saturates the water phase, the complex
will crystallize or precipitate.
Paste complexation. – A small amount of water is added to the guest to form a paste,
which is mixed with the CD using a mortar and pestle. The resulting complex can be
dried directly, and milled if hard mass forms.
Damp mixing. – The guest and CD are thoroughly mixed and placed in a sealed con-
tainer with a small amount of water. The contents are heated to about 100 °C and then
removed and dried.
Extrusion. – CD, guest and water can be premixed or mixed as added to the extrud-
er. The extruded complex may dry as it cools or the complex may be placed in an oven
to dry. Heat-labile guests can get decomposed.
Dry mixing. – Some guests can be complexed by simply adding the guest to the CD
and mixing them together. This works best with oils or liquid guests.
In all above methods, optimization of the amount of water, degree and time of mix-
ing, temperature and heating time is necessary for each guest.
Different mechanisms play an important role in drug release from the drug-CD
complex. Complexation of the drug (D) to CD occurs through a non-covalent interaction
between the molecule and the CD cavity. This is a dynamic process whereby the drug
molecule continuously associates and dissociates from the host CD. Assuming a 1:1






Two parameters, the complexation constant (K) and the lifetime of the complex, are
very important for the drug release mechanism.
Dilution. – Dissociation due to dilution appears to be a major release mechanism.
The recent example reported by Piel et al. (11) for miconazole, a more strongly bound
drug compared to prednisolone (12), supports the probable role of dilution. Dilution is
minimal when a drug-CD complex is administered ophthalmically. Efficient corneal ab-
sorption is further exacerbated by contact time.
Competitive displacement. – Competitive displacement of drugs from their CD com-
plexes probably plays a significant role in vivo. Addition of parabens to parenterals not
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only leads to decreased antimicrobial activities of the parabens, due to complexation, but
also decreases the drug solubility due to its displacement from complexes (13). Van Stam
et al. (14) showed that alcohol displaces 2-napthol from -CD complexes. Tokumura et al.
(15, 16) reported that the -CD complex of a poorly water-soluble drug, cinnarizine, was
more soluble in vitro than cinnarizine alone. Oral administration of the complex showed
less bioavailability than expected, based on the in vitro dissolution experiments. It was
suggested that cinnarizine was too strongly bound to the CD so that complex dissocia-
tion was limiting oral bioavailability. Co-administration of phenylalanine, a displacing
agent, improved the bioavailability of cinnarizine from the complex but not from con-
ventional cinnarizine tablets.
Protein binding. – Drug binding to plasma proteins may be an important mechanism
by which the drug may be released from a drug-CD complex. It is evident that proteins
may effectively compete with CDs for drug binding and thus facilitate the in vivo release
of drugs from drug-CD complexes. Dilution alone may be effective in releasing free drugs
from weak drug-CD complexes but when the strength of the binding between the drug
and CD is increased, a mechanism such as competitive displacement is at work. Plasma
and tissue protein binding may also play a significant role. Frijlink et al. (17) studied the
effect of HP--CD on the displacement of both naproxen and flurbiprofen from plasma
binding sites in vivo. They found that tissue distribution of flurbiprofen and naproxen
was higher when HP--CD-drug solution was administered compare to drug solution in
plasma, 10 minutes after parenteral dose, meaning that more drug was free from CD so-
lution to distribute to the tissues than from the plasma solution.
Drug uptake by tissue. – A potential contributing mechanism for drug release from
CD is preferential drug uptake by tissues. When the drug is lipophilic and has access to
tissue, and is not available to the CD or the complex, the tissue then acts as a »sink«,
causing dissociation of the complex based on simple mass action principles. This mecha-
nism is more relevant for strongly bound drugs or when the complex is administered at
a site where dilution is minimal, e.g., ocular, nasal, sublingual, pulmonary, dermal or
rectal sites. For example, CD has been used in ophthalmic delivery of poorly water-solu-
ble drugs to increase their solubility and/or stability in the tear fluid, and in some cases
to decrease irritation (18, 19).
Change in ionic strength and temperature. – In the case of a weak electrolyte, the strength
of binding to CD is dependent on the charged state of the drug, which is dependent on
dissociation constant(s) of the drug and the pH of environment. For most molecules, the
ionized or charged form of the molecule has poorer binding to CD compared to the non-
-ionized or neutral form of the drug, especially when bound to a neutral CD (12, 20, 21).
Loftsson et al. (22) and Inoue et al. (23) have shown that binding of substrate to CD is an
exothermic process. Hence any increase in temperature results in a weakening of the
complex and thus increases the free fraction of substrate. Drug-CD complexes are usu-
ally prepared and stored at/or below room temperature. Since the normal body tissue
temperature can be as high as 37 °C, this difference in temperature may be another con-
tributing factor to drug dissociation in vivo.
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CYCLODEXTRINS IN OPHTHALMIC DRUG DELIVERY
Local drug administration to the eye is preferred to systemic drug administration
(oral route). This route can avoid the effects influencing gastrointestinal absorption such
as pH, food, stomach emptying, etc. Topically applied drug formulations such as sus-
pensions, oily drops, gels, ointments and solid inserts have been used, but most of these
formulations give rise to unwanted side effects (e.g., eye irritation and blurred vision)
(24). Some investigators suggest that CDs enhance drug permeability through biological
membranes such as eye cornea and skin by disrupting the membrane, either by perme-
ating into the membrane or by extracting or complexing with some lipophilic compo-
nents such as cholesterol and phospholipids from the membrane (25). But, the correct
mechanism is when CD acts as a true carrier by keeping the hydrophobic drug mole-
cules in solution and delivers them through the aqueous mucin layer to the surface of
the ocular barrier (i.e., cornea or conjunctiva) where they partition into the barrier.
Ophthalmic irritation is a common drawback in ophthalmic drug development and
in their clinical use. CDs may decrease the irritation of ophthalmic drugs by forming in-
clusion complexes and thereby masking the irritating drugs or by replacing the irritating
additives from the formulation. Co-administration of HP--CD (26), SBE4--CD (i.e.,
SBE--CD with the average degree of substitution of 4) (27) or SBE7--CD (substitution
degree 7) (28) significantly decreases eye irritation of the pilocarpin prodrug. Pilocarpin
irritation is due to the rapid absorption of the lipophilic prodrug into the lipophilic cor-
neal epithelium and/or precipitation of prodrug molecules in the pre-corneal area. Pilo-
carpin/SBE 7--CD complexes can be considered to act as a depot that limits the free
prodrug concentration in the precorneal area to a non-irritating level. Similarly, cetiri-
zine, an antiallergic drug, causes strong irritation after ophthalmic administration but
co-administration of -CD, -CD and -CD eliminates this irritation (29).
Ophthalmic solutions are usually aqueous solutions in which most drugs are sub-
ject to chemical degradation. One of the most common pharmaceutical applications of
CDs is to enhance drug stability in aqueous solutions. Dipivefrine, a prodrug of epine-
phrine, has currently replaced epinephrine in the treatment of glaucoma. The main draw-
back of dipivefrine is its low aqueous stability. In eye drops, this has been overcome by
formulating a dipivefrine solution in the pH range of 2.5 to 3.5 (30). However, the eye
drop is irritating to the eye, resulting in decreased ocular bioavailability due to induced
lacrimation (31). At pH 5 and pH 7.4, the negatively charged SBE7--CD increases the
aqueous stability of positively charged dipivefrine 15–30 times and 20–200 times, respec-
tively. Commercial pilocarpin eye drops are buffered between pH 4 and 5 for stability.
SBE 4--CD increases the aqueous stability of pilocarpin at pH 6–8 as much as twofold
(32). Hydrocortisone can be formulated as a water solution in the presence of HP--CD
and the aqueous stability of hydrocortisone was increased approximately twofold at 60 °C
due to complexation (33). Considerable improvement in the chemical and enzymatic sta-
bility of ganciclovir prodrugs was observed in the presence of HP--CD. HP--CD was
found to enhance the corneal permeation only of the lipophilic prodrugs of ganciclovir (34).
Unfortunately, there are some limitations to the of CDs application in ophthalmic
drug delivery. Pilocarpin is stabilized by SBE 4--CD in aqueous solution but the bio-
availability of the drug is affected. Freedman et al. (35) showed that at a low concentra-
tion, co-administration of SBE 4--CD has no effect on pilocarpin bioavailability and it
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has even a slight decreasing effect at higher concentrations (32). Similarly, HP--CD has
been shown to slightly reduce the efficacy of water-soluble timolol for intraocular pres-
sure in rabbits. The decreased bioavailability is, in most cases, due to a fast clearance of
the drug-CD complex from the precorneal area. This problem can be, at least partly, over-
come by increasing the viscosity (and hence the residence time) of eye drops. In vitro
(36–38) and in vivo (24, 28) studies have shown that excess complexation of a poorly wa-
ter-soluble drug will decrease its membrane permeability and ophthalmic viability.
Eye drops are usually delivered in a multi-dose container and thus should contain
an antimicrobial preservative. CD complexation with the preservative can reduce their
antimicrobial activity. Lipophilic preservatives such as p-hydroxy benzoic acid esters form
complexes with HP--CD and their antimicrobial effect decreases (39–41). Contrary to
this, the antimicrobial effect of hydrophilic preservatives like thimerosal, bronopol (41),
benzalkonium chloride and chlorohexidine gluconate (40) are not much affected since
they are not as effectively bound to CDs.
CYCLODEXTRINS IN NASAL DRUG DELIVERY SYSTEM
Nasal route is an alternative and convenient route for administration of high po-
tency drugs with low oral bioavailability because of their extensive gastrointestinal bre-
akdown and high hepatic first-pass effect. Drugs of a lipophilic nature are difficult to de-
liver through the nasal route due to their poor water solubility. Large hydrophilic drugs
like peptides and proteins show insufficient nasal absorption. One more drawback of
this route is large interspecies differences exist in the nasal absorption of drugs. Also,
the nasal mucosa possesses enzymatic activity as a protective mechanism against exoge-
nous chemicals.
Methylated derivatives of CD, especially -CD and -CD, have been proven to be
excellent solubilizer and absorption enhancers. However, studies on RM--CD (20% and
above) have revealed severe damage to the nasal mucosa integrity (42). Recent investi-
gations of lipophilic drugs in the nasal drug delivery system with CD involved estradiol
(decrease in dose) (43, 44), morphine HCl (45), midazolam (46) (enhanced nasal absorp-
tion), dihydroergotamine (improved stability) (47). Administration of lipophilic drugs
such as female steroid hormones estradiol and progesterone with CDs has shown rapid
absorption (43, 44). Intranasal spray of the antiviral lipophilic drug pirodavir with 10%
hydroxypropyl--CD as solubilizer was effective in preventing rhinovirus infection (50).
Side effects such as nasal dryness and blood in mucus were attributed to the viscosity of
the formulation vehicle and high frequency of administration. Dimethyl--CD and 2-hy-
droxypropyl--CD has shown an enhanced and sustained level of morphine in the plasma
and cerebrospinal fluid (45). CDs have been also shown to enhance the concentration
and improve the stability of the antimigraine drug dihydroergotamine. Melatonin in com-
bination with -CD has been investigated as well. The nasal absorption appeared to be
very fast and efficient, in contrast the oral bioavailability of melatonin, which is low and
variable due to the first pass metabolism (51).
Hydrophilic drugs, e.g., proteins and peptides, have low nasal absorption in hu-
mans that decreases with increasing molecular size. CD has shown increased nasal ab-
sorption of oligopeptide drugs like buserelin (52) and leuprolide (53). At a 5% concentra-
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tion, methylated--CD significantly increased calcitonin nasal absorption compared to
intravenous or subcutaneous administration (54). Increased nasal bioavailability of glu-
cagons (55) and insulin (56) with dimethyl--CD has been reported. It can be concluded
from the various studies that most nasal absorption enhancing CDs for peptides and
proteins are methylated -CD derivatives, DM--CD.
Bioavailability after nasal administration of insulin to rats increased up to 100% with
dimethyl--CD (3–5%) (54). When the concentration of dimethyl--CD in nasal liquid
formulations was increased to 50%, the insulin bioavailability dropped markedly. The
decreased absorption was possibly due to administration of extremely high concentra-
tions of CD or the excess of CD interfered with the insulin transport across the nasal epi-
thelium (57).
CYCLODEXTRINS IN TRANSDERMAL DRUG DELIVERY
Drugs have been delivered by the transdermal route for both local and systemic ac-
tion. As the drug enters systematic circulation directly, the first pass effect is eliminated;
it also eliminates the factors that influence gut absorption. This route can be used for
drugs with a low therapeutic index. The transdermal drug transport is greatly limited
by stratum corneum permeation characteristics; so attempts at improving topical ab-
sorption have been reported. Drugs must retain sufficient stability, not only during stor-
age but also at the site of application. Various studies report CD as a drug stabilizer in
dermal drug delivery. Complex of dermatocorticoid, tixoxortol-17-butyrate-21-propio-
nate, with -CD included in vaseline and o/w emulsion showed stability after 30 days
storage at 40 °C (58). Uekama et al. (59) reported that CME--CD markedly stabilized
prostaglandin E1 (PGE1) in fatty alcohol/propylene glycol (FAPG) ointment and in aqu-
eous solution. Adachi et al. (60) reported stabilizing effects of CD against the decomposi-
tion of PGE1 in the skin. The combination of CME--CD and topical permeation enhancer,
1-2-(decylthio) ethyl-azacyclopentane-2-one, suppressed the bioconversion of PGE1 to
give less pharmacologically active metabolites during the passage through the skin.
A number of reports reported improved drug release from the vehicle and perme-
ation as CDs complexes. Dermal corticoids like betamethasone (61) and beclamethasone
dipropionate (62) showed enhanced release from hydrophilic ointment bases after com-
plexation with -CD and/or -CD. Vehicle types used markedly affect the enhancing ef-
fect of CDs on the drug release, e.g., prednisolone complexation with dimethyl -CD in
non-aqueous ointment bases such as macrogol decreases the release. These decreasing
effects of the hydrophilic CDs may be due to the lowering of the drug solubility via the
complex formulation (63). CDs are also able to enhance the dermal delivery of NSAIDs.
Arima et al. (64) have shown increased in vivo absorption of 4-biphenyl acetic acid in rats
due to complexation with -CD, DM--CD and HP--CD. Lin et al. (65) reported that the
anti-inflammatory effects of indomethacin in hydroxyethylcellulose hydrogels, a hydro-
philic base, were significantly enhanced by complexation with -CD and HP--CD in
healthy volunteers. This can be due to permeation enhancement of lipophilic drugs such
as corticosteroids and NSAIDs through the skin by increasing the drug thermodynamic
activity in water containing vehicles. Further addition of CDs to the systems decreases
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the permeation rate of lipophilic drugs through the formation of strong complexes (66).
In addition, Loftsson et al. (67, 68) reported the possibility that addition of ternary mate-
rials to the vehicle affected the enhancing effects of CDs on dermal drug delivery. Con-
sidering the effects of hydrophilic CDs on drug release, hydrophobic CD may alter the
drug release from the vehicle. For example, the release rate of nitroglycerin from oint-
ments was accelerated by complexation with DE--CD, and retarded by complexation
with -CD. Therefore, a combination of DE--CD and -CD complexes might be applica-
ble to sustained release preparations for percutaneous administration (69, 70). This in-
creased permeability may be due to CDs interaction with some component of the skin.
CDs are also being identified as co-enhancers in dermal drug delivery systems. This
statement is supported by Legendre et al. (71) who showed that a combination of oleic
acid, a permeation enhancer, and RM--CD increased the flux of S-9977 hydrochloride
30 fold due to the increase in the diffusion of oleic acid in stratum corneum.
Recently, CDs in dermal delivery of proteins and peptides has been noted. For ex-
ample, a combination of -CD and the permeation enhancer Azone achieved higher per-
cutaneous absorption of a peptide drug, nafarelin acetate, and a luteinizing hormone re-
leasing analog (72). CDs may alleviate skin irritation caused by drugs by lowering the
extent of free drug resulting from the inclusion equilibrium. Hoshino et al. (73) studied
the effect of topically applied -CD and DM--CD on photoallergic contact dermatitis of
chlorpromazine HCl in guinea pig and found a decreased photosensitizing potential of
chlorpromazine HCl with -CD and DM--CD compared to chlorpromazine HCl alone.
The alleviating effects of CDs may be explained by the suppression of the penetration of
chlorpromazine HCl into the skin via the lower partition coefficient between drug and
skin. Studies show that at higher concentrations parent CDs and chemically modified
CDs caused skin irritation in guinea pigs in the order -CD < -CD < -CD; this result
largely depends on their abilities to extract lipids from stratum corneum (74). As regards
CD derivatives, DM--CD is known to extract the components from stratum corneum,
which leads to skin irritation.
CYCLODEXTRINS IN RECTAL DRUG DELIVERY
Rectal route is the alternative drug application route for patients who have difficul-
ties in swallowing, nausea or vomiting, for infants or children. However, rectal drug de-
livery is limited by the dissolution media volume, low rectal bioavailability of some
drugs, limited absorbing surface and drug degradation by microorganisms present in
the rectum. Usefulness of CDs for rectal drug delivery has been reported with respect to
stabilization, improvement in release, bioavailability and alleviation of local irritation (75).
Many reports concluded that the effect of CDs on rectal drug delivery depends so-
lely on the vehicle type (hydrophilic or lipophilic), physicochemical properties of the
complexes and addition of ternary excipients such as viscous polymers. Enhancement of
rectal absorption of lipophilic drugs is based on the improvement of drug release from
vehicles and the dissolution rates in rectal fluid. In the case of inabsorbable drugs like
antibiotics, peptides and proteins, CDs directly act on the rectal epithelial cells. CDs drug
complexes improve the chemical stability of the drugs in suppository bases and reduce
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the drugs bioconversion to pharmacological inactive metabolites in the rectum. For ex-
ample, AD-1590, an acidic NSAID, with -CD prevents its auto-oxidation (76). These sta-
bilizing effects of CDs are attributed to insolubilization of the drugs in the lipophilic
suppository base. Arima et al. (77) reported inhibition of ethyl-4-biphenylyl acetate (EBA)
bioconversion in the rectal lumen of rats by complexation with -CD, DM--CD and
HP--CD using the in situ recirculation technique. Complexed EBA was less absorbable
from the rectal lumen in the solution state; this inhibited the bioconversion of EBA to
BPAA. These inhibitory effects may also lead to decreased rectal irritation of the drug.
-CD in combination with xanthan gum has been reported to inhibit the bioconversion
of morphine in rabbit rectum. CD inhibits the upward movement of morphine from ar-
eas affected by the first pass metabolism and thereby conversion to less active morphi-
ne-glucoronoid conjugates (78).
Watanabe et al. (79, 80) reported that CDs enhanced the permeability of proteins
such as insulin and recombinant human granulocyte colony stimulating factor through
the rectal epithelial cells of rabbits. CDs have been also reported as co-enhancers. Along
with the fact that CDs reduce gastrointestinal mucosa irritation, CDs have also been re-
ported to reduce rectal irritation caused by NSAIDs. For example, HP--CD significantly
reduced the irritation of rectal mucosa caused by BPAA and EBA administration of lipo-
philic suppositories to rats (77, 81).
CYCLODEXTRINS IN ORAL DRUG DELIVERY
Oral modified release is of growing interest because appropriate drug release from
dosage forms is of critical importance for their therapeutic efficacy. CDs are potential
candidates for modified release carriers because they can form inclusion complexes both
in solution and in the solid state, in which the guest molecule is surrounded by the hy-
drophobic environment of the CD cavity. Chemically modified hydrophobic and hydro-
philic CDs may serve as novel slow-release carriers for water-soluble drugs, including
proteins and peptide drugs, and enhance drug absorption.
Immediate release. – The dissolution rate of poorly water-soluble drugs is mainly re-
sponsible for both the rate and extent of oral bioavailability of drugs. Hydrophilic CDs
have been extensively used to enhance the oral bioavailability of steroids, NSAIDs, car-
diac glycosides, antiepileptics, benzodiazepines, antidiabetics, vasodilators, etc. (82). These
improvements are mainly attributed to the increase in solubility and wettability of drugs
through the formation of inclusion complexes. Only the free form of the drug, which is
in equilibrium with the complexed form of the drug in solution, is capable of penetrat-
ing the lipophilic barriers and thus entering the systemic circulation. Displacement of
the drug from the CD cavity by exogenous (excipient) and endogenous substances (which
compete with the drug for the CD cavity) at the absorption site is one of the factors re-
sponsible for acceleration of drug absorption. Therefore, the application is successful
when the rate-limiting step in drug absorption is the dissolution of the drug itself and
not its absorption across the gastrointestinal tract. Complexation of -CD with imidazole
antifungal agents, such as ketoconazole and econazole, provides enhanced bioavailabi-
lity (83, 84). The stabilizing effect of CDs on labile drugs is also responsible for the im-
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provement of oral bioavailability. For example, the -CD complex decreases acid hydro-
lysis of cardiac glycosides and thus improves the oral absorption of digoxin in dogs (85).
Highly hydrophilic CD derivatives, such as HP--CD (86), maltosyl--CD (87) and SBE--CD
(88) have been used to obtain an immediate release formulation that is readily dissolved
in GIT, enhancing the oral bioavailability of poorly water soluble drugs. Rapidly dis-
solving complexes of drugs and CDs are well suited for sublingual or buccal administra-
tions, which avoid the hepatic first-pass metabolism of the drug. HP--CD and -CD
support the absorption of testosterone from the oral cavity rather than GIT.
Delayed release. – Delayed release can be classified as time controlled release, since
the drug is preferentially released in the intestinal tract. Excipients having weak acidic
groups are preferable because they are less soluble in water at low pH. CME--CD was
developed to exhibit pH-dependent solubility for use in selective dissolution of the drug
CD-complex. Molsidomine absorption from tablets containing CME--CD was studied
in gastric acidity-controlled dogs in fasted and fed states. Under high gastric acidity,
molsidomine absorption was significantly retarded compared to that found under low
gastric acidity conditions. The delayed absorption effect under high gastric acidity was
more pronounced under fasted conditions (89).
Prolonged release. – Slow-release preparations have been designed to achieve zero-or-
der or pH-independent release of drugs to provide a constant blood level for a long pe-
riod of time. These formulations have advantages such as reduced dosing frequency,
prolonged drug efficacy and absence of toxicity associated with the administration of a
simple plain tablet. Hydrophobic alkylated CDs such as DE--CD, TE--CD were the
first slow-release carriers to be used in conjugation with diltiazem (90).
Modified release. – Nifedipine has low oral bioavailability due to its poor aqueous
solubility; hence the release rate of nifedipine must be modified in order to obtain a
more balanced oral bioavailability with therapeutic effect. Wang et al. (91) developed a
double-layer tablet employing an amorphous nifedipine powder prepared by spray dry-
ing with HP--CD and HCO-60® (non-ionic detergent) as the fast release portion to at-
tain initial rapid dissolution. Recently, Okimoto et al. (92) developed a novel osmotic
pump tablet for prednisolone using (SBE)7m--CD, which acts as a solubilizer and an
osmotic agent.
CONCLUSIONS
Dissociation due to dilution appears to be the major release mechanism from CD
inclusion complexes. CDs are useful additives in ophthalmic formulations for increasing
the aqueous solubility, stability and bioavailability of ophthalmic drugs, and for decreas-
ing drug irritation. Methylated -CDs have been shown to be useful excipients in nasal
drug delivery. The in vivo study demonstrates that they can largely improve the nasal
absorption of some lipophilic drugs and of oligopeptides. The effects of CDs on the re-
lease, topical bioavailability and pharmacological effects of drugs when applied to the
skin and into the rectum are considerably influenced by the vehicle type. A desirable at-
tribute to the drug carrier is the ability to control the rate and time of drug release; pera-
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cylated CDs may serve as novel hydrophobic carriers to control the release rate of wa-
ter-soluble drugs. We hope that further investigations on CDs will overcome some of the
problems related to producing larger, labile complexes, insoluble and/or inabsorbable
drugs in the near future.
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Acronyms. – CD – cyclodextrin; CME--CD – O-carboxymethyl-O-ethyl -CD; DE--CD – 2,6-di-
ethyl--CD; HP--CD – 2-hydroxypropyl--CD; DM--CD – 2,6-dimethyl--CD; SBE--CD – sulfate
and sulfobutylether--CD; RM--CD – randomized methylated--CD; BPAA – 4-biphenyl acetic acid;
EBA – ethyl 4-biphenylyl acetate; GIT – gastrointestinal tract; NSAID – non-steroidal anti-inflamma-
tory drug.
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S A @ E T A K
Ciklodekstrini – primjena u razli~itim na~inima isporuke lijekova
SHYAM SHIMPI, BHASKAR CHAUHAN i PRAJAKTA SHIMPI
U ovom revijalnom radu opisana su fzi~ko-kemijska svojstva ciklodekstrina, razli~iti
na~ini njihove primjene te mehanizmi osloba|anja ljekovitih tvari iz kompleksa s ciklodeks-
trinima (razrje|enje, kompetitivna zamjena, vezanje na proteine, promjena ionske jakosti
i temperature, te unos ljekovite tvari u tkivo). Opisana je uporaba ciklodekstrina i ograni-
~enja uporabe u razli~itim sustavima za isporuku lijekova za nazalnu, oftalmi~ku, trans-
dermalnu, rektalnu te detaljno za peroralnu primjenu. Mnogobrojna istra`ivanja su potvrdila
da su ciklodekstrini korisni sastojci pripravaka za razli~ite na~ine primjene jer pove}avaju
vodotopljivost, stabilnost i bioraspolo`ivost ljekovite tvari, a smanjuju njenu iritabilnost.
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